બાયોકોન શેરની કિંમત

<h3><span style="font-size:16px;"><strong>બાયોટેકનોલોજી કંપની બાયોકોનએ Q1FY27 પરિણામોની જાહેરાત કરી</strong></span></h3><p _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">કન્સોલિડેટેડ ફાઇનાન્શિયલ હાઇલાઇટ્સ:</strong></p><ul><li _ngcontent-ng-c1006311636="">Total Income: The consolidated total income for Q1FY27 was Rs 43,905 million, reflecting a decrease of 3.91% from Rs 45,691 million in Q4FY26, but an increase of 9.17% from Rs 40,216 million in Q1FY26. For the full year FY26, total income reached Rs 1,72,695 million.</li><li _ngcontent-ng-c1006311636="">Revenue from Operations: Consolidated revenue from operations stood at Rs 43,360 million in Q1FY27, showing a growth of 10.00% YoY from Rs 39,419 million in Q1FY26 and a decrease of 4.00% QoQ from Rs 45,166 million in Q4FY26.</li><li _ngcontent-ng-c1006311636="">Net Profit for the Period: The company reported a consolidated net profit of Rs 1,368 million in Q1FY27, representing a growth of 53.36% compared to Rs 892 million in Q1FY26. On a QoQ basis, profit decreased by 31.12% from Rs 1,986 million in Q4FY26. The net profit for the full year FY26 was Rs 3,688 million.</li><li _ngcontent-ng-c1006311636="">Profit Before Tax (PBT): Consolidated PBT for Q1FY27 was Rs 1,276 million, compared to Rs 2,475 million in Q4FY26 (down 48.44%) and Rs 969 million in Q1FY26 (up 31.68%).</li><li _ngcontent-ng-c1006311636="">શેર દીઠ કમાણી (EPS): Q4FY26 માં ₹0.79 અને Q1FY26 માં ₹0.26 ની તુલનામાં Q1FY27 માટે બેસિક અને ડાઇલ્યુટેડ EPS ₹0.87 છે. The full year FY26 EPS was Rs 2.82.</li></ul><p _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">સ્ટેન્ડઅલોન ફાઇનાન્શિયલ હાઇલાઇટ્સ:</strong></p><ul><li _ngcontent-ng-c1006311636="">Total Income: Standalone total income in Q1FY27 was Rs 6,893 million, an increase of 5.32% from Rs 6,545 million in Q4FY26 and an increase of 15.19% from Rs 5,984 million in Q1FY26. For FY26, standalone total income was Rs 26,661 million.</li><li _ngcontent-ng-c1006311636="">Revenue from Operations: Standalone revenue for Q1FY27 reached Rs 6,245 million, representing an increase of 3.27% QoQ from Rs 6,047 million in Q4FY26 and an increase of 16.27% YoY from Rs 5,371 million in Q1FY26.</li><li _ngcontent-ng-c1006311636="">Net Profit: Standalone net profit for Q1FY27 stood at Rs 522 million, compared to Rs 510 million in Q4FY26 and a net loss of Rs 83 million in Q1FY26. The standalone net profit for FY26 was Rs 372 million.</li><li _ngcontent-ng-c1006311636="">Profit Before Tax (PBT): Standalone PBT was Rs 699 million in Q1FY27, compared to Rs 574 million in Q4FY26 and a loss of Rs 76 million in Q1FY26.</li><li _ngcontent-ng-c1006311636="">Earnings Per Share (EPS): Standalone basic and diluted EPS for Q1FY27 was Rs 0.32, compared to Rs 0.32 in Q4FY26 and a negative Rs 0.07 in Q1FY26.</li></ul><p _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">બિઝનેસ હાઇલાઇટ્સ:</strong></p><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">સેગમેન્ટ પરફોર્મન્સ:</strong><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Biosimilars:</strong> This segment generated revenue of Rs 28,556 million in Q1FY27, up 3.63% from Rs 27,556 million in Q4FY26 and up 16.18% from Rs 24,578 million in Q1FY26. Segment profit before tax was Rs 1,714 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Generics:</strong> Revenue from the Generics segment was Rs 7,597 million in Q1FY27, compared to Rs 7,760 million in <strong _ngcontent-ng-c1006311636="">Q4FY26</strong> and Rs 6,303 million in Q1FY26. The segment reported a loss of Rs 309 million.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Services:</strong> Revenue for the Services segment stood at Rs 7,360 million in Q1FY27, down from Rs 10,365 million in Q4FY26 and Rs 8,745 million in Q1FY26. The segment results showed a loss of Rs 57 million.</li></ul></li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Ownership Consolidation:</strong> Biocon Biologics Limited (BBL) became a wholly-owned subsidiary of Biocon Limited effective June 29, 2026. This followed the acquisition of 1,15,36,956 equity shares of BBL from selling shareholders through a share swap transaction, for which 87,86,362 equity shares of Biocon Limited were allotted on a preferential basis.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Subsidiary Liquidation:</strong> The Board and shareholders of Syngene International Limited approved the voluntary liquidation of its wholly-owned subsidiary, Syngene Manufacturing Limited, on June 15, 2026.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Exceptional Items:</strong> Consolidated exceptional items in Q1FY27 included a net charge of Rs 135 million, primarily pertaining to termination benefits.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Dividend:</strong> The Board of Directors of the company recommended a final dividend of Rs 0.50 per equity share of face value Rs 5 for the financial year FY26, subject to shareholder approval.</li></ul><p><strong>Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said:</strong> “Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market. We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth.”</p><p><strong>Shreehas Tambe, CEO & Managing Director, Biocon, said:</strong> “Biocon delivered a resilient performance in Q1FY27, reporting consolidated revenue from operations growth of 10% year-on-year to Rs 4,336 crore and EBITDA of Rs 902 crore. This reflects the strength of our diversified portfolio and disciplined commercial execution. In FY27, we have successfully launched Bosaya™? and Aukelso™? (biosimilar Denosumab), Yesafili™ (biosimilar Aflibercept), and generic Liraglutide, further strengthening our presence in the U.S. market. We also secured regulatory approval from the European Medicines Agency (EMA) for our new drug product fill-finish plant for insulins in Malaysia, unlocking additional manufacturing capacity. Our focus on balance sheet optimization reduced interest costs by 23% year-on-year. We expect growth momentum to accelerate through the year, driving a stronger second-half performance.”</p><p><strong>Siddharth Mittal, CEO & Managing Director, Syngene International, said:</strong> “As I take charge of Syngene, amid headwinds that the Company is currently navigating, I look forward to working closely with the Board and our leadership team to sharpen our focus and translate our priorities into tangible business outcomes that will provide a strong foundation for long-term growth. My immediate priorities are to sharpen our commercial execution, strengthen delivery across our businesses, and build a more agile, cost-competitive organization. At the same time, we will continue to invest in CDMO, AI, innovation and differentiated scientific capabilities that will strengthen our competitive position.”</p><p><a class="lb" href="/gujarati/get-document/post/pdf/5766892/" target="_blank">પરિણામની PDF</a></p>

• ટ્રેન્ડલાઇન
• 2 કલાક 19 મિનિટ પહેલાં

મૉનિટરિંગ એજન્સી રિપોર્ટ

• BSE ઇન્ડિયા
• 2 કલાક 24 મિનિટ પહેલાં

પ્રેસ રિલીઝ

• BSE ઇન્ડિયા
• 2 કલાક 32 મિનિટ પહેલાં